ライフサイエンスコーパス: fasting plasma glucose

1 ment induced glucosuria and markedly lowered fasting plasma glucose.

2 2 inhibition, despite an overall decrease in fasting plasma glucose.

3 e impact of type 2 diabetes risk variants on fasting plasma glucose.

4 e residue content correlated positively with fasting plasma glucose.

5 intervention-induced improvement in A1C and fasting plasma glucose.

6 es, who were matched for body-mass index and fasting plasma glucose.

7 The primary outcome was reduction in fasting plasma glucose.

8 P < 0.0001) but did not prevent the rise in fasting plasma glucose.

9 or elevated triglycerides, 18.95% for raised fasting plasma glucose.

10 aining current levels of body mass index and fasting plasma glucose.

11 -0.74, -0.01; P = 0.04) and had no effect on fasting plasma glucose.

12 ), once-weekly exenatide and albiglutide for fasting plasma glucose (-0.7 mmol/L [CI, -1.1 to -0.2 mm

13 ration 10 years; HbA(1c) 8.5% [69 mmol/mol]; fasting plasma glucose 10 mmol/L).

14 Pioglitazone reduced fasting plasma glucose (10.0 +/- 0.7 to 7.5 +/- 0.6 mmol

15 Significant improvements in fasting plasma glucose (104.2 +/- 7.8 vs. 86.7 +/- 3.1 m

16 and pioglitazone also significantly improved fasting plasma glucose (-11+/-14 mg/dL; P=0.003), althou

17 categorized by the 1997 ADA IFG definition (fasting plasma glucose 110 to 125 mg/dl; 6.1 to 6.9 mmol

18 a significant decrease in concentrations of fasting plasma glucose (-17.1 +/- 14.8 compared with -0.

19 RSG improved fasting plasma glucose (185 +/- 8 to 139 +/- 5 mg/dl), m

20 Furthermore, no significant differences in fasting plasma glucose (2.9%; 95% CI: -0.4, 6.3%; P = 0.

21 ctors of type 2 diabetes mellitus, including fasting plasma glucose, 2-h post-load plasma glucose, an

22 od that was superior to clinical parameters (fasting plasma glucose, 2-hour plasma glucose).

23 Secondary outcomes included fasting insulin, fasting plasma glucose, 2-hour plasma glucose, and lipid

24 Fasting plasma glucose (5.4 +/- 0.1 vs. 5.1 +/- 0.1 mmol

25 ascular disease mortality, and patients with fasting plasma glucose 70 to 79 mg/dL (3.89 to 4.43 mmol

26 risk compared with the risk in patients with fasting plasma glucose 80 to 109 mg/dL (4.44 to 6.05 mmo

27 on 13.5 years [7.3], HbA(1c) 8.3% [0.8], and fasting plasma glucose 9.2 mmol/L [3.1]); 618 (82%) and

28 ge 51 +/- 4 years, BMI 29.3 +/- 1.4 kg/m(2), fasting plasma glucose 9.3 +/- 0.7 mmol/l) during an int

29 Changes in fasting plasma glucose (-9.7 +/- 10.1 vs. +1.8 +/- 8.1 m

30 Compared with participants who had normal fasting plasma glucose, abnormal heart rate recovery was

31 systolic blood pressure, dietary risks, high fasting plasma glucose, air pollution, and high LDL chol

32 more abnormal across categories of worsening fasting plasma glucose (all P <0.05).

33 coverage practices had 0.2 mmol/L lower mean fasting plasma glucose and 0.9% lower cardiovascular ris

34 d variants of rs2269023 were associated with fasting plasma glucose and 1-hour plasma glucose during

35 th the G/G-genotype had significantly higher fasting plasma glucose and 2-h insulin concentrations af

36 estriction and liraglutide treatment lowered fasting plasma glucose and A1C concentrations compared w

37 LB/cJ (BALB) exhibit distinct differences in fasting plasma glucose and atherosclerotic lesion size w

38 especified secondary outcomes were levels of fasting plasma glucose and glycated hemoglobin, insulin

39 ar thickness (at 1 mm) and the levels of the fasting plasma glucose and glycosylated hemoglobin (HbA1

40 Fasting plasma glucose and glycosylated hemoglobin conce

41 lications yet test reliability is better for fasting plasma glucose and hemoglobin A1c than for the o

42 During pregnancy, fasting plasma glucose and hepatic glucose production we

43 uch as undernutrition, were replaced by high fasting plasma glucose and high body-mass index by 2013.

44 Whereas fasting plasma glucose and high-sensitivity C-reactive p

45 aglitazar for 3 months significantly lowered fasting plasma glucose and homeostasis model assessment

46 Fasting plasma glucose and insulin concentrations were m

47 tment for age, sex, percentage body fat, and fasting plasma glucose and insulin concentrations).

48 lin resistance (HOMA-IR) was calculated from fasting plasma glucose and insulin concentrations.

49 The mice also exhibit lower fasting plasma glucose and insulin levels and an increas

50 In addition, fasting plasma glucose and insulin levels increased and

51 Fasting plasma glucose and insulin were significantly hi

52 We measured serum lipids and lipoproteins, fasting plasma glucose and insulin, blood pressure (BP),

53 Fasting plasma glucose and lipid concentrations were als

54 litus, and who had available measurements of fasting plasma glucose and lipid concentrations within t

55 Fasting plasma glucose and lipid levels were measured be

56 r, there were no significant differences for fasting plasma glucose and lipid profiles within both gr

57 We documented a U-shaped relation between fasting plasma glucose and mortality.

58 l group comprised 64 individuals with normal fasting plasma glucose and normal glucose tolerance.

59 iated with cardiovascular disease, including fasting plasma glucose and possibly HDL-C.

60 s also suggested an inverse association with fasting plasma glucose and serum C-reactive protein but

61 l (TAD) will attenuate inflammation, improve fasting plasma glucose and triglyceride levels, body wei

62 Treatment with leptin normalized fasting plasma glucose and was accompanied by lowered Hb

63 and 46 patients with pre-DM showing impaired fasting plasma glucose and/or impaired oral glucose tole

64 (oral glucose tolerance test, basal insulin, fasting plasma glucose) and 1 postdonation RF, greater t

65 4 trials on waist circumference, 4 trials on fasting plasma glucose, and 5 trials on C-reactive prote

66 On stepwise multivariate analysis, age, sex, fasting plasma glucose, and BMI were the most important

67 sex, self-reported physical activity level, fasting plasma glucose, and BMI were used.

68 Atherosclerotic lesions in the aortic root, fasting plasma glucose, and body weight were measured.

69 20 mg, showed a greater reduction of HbA1c, fasting plasma glucose, and body weight.

70 llicle-stimulating hormone (FSH), prolactin, fasting plasma glucose, and insulin levels were measured

71 lycemic markers (HbA(1C) [hemoglobin A(1C)], fasting plasma glucose, and insulin resistance-homeostas

72 x group interaction for waist circumference, fasting plasma glucose, and lipid profiles within both g

73 tio, body mass index, fasting serum insulin, fasting plasma glucose, and type 2 diabetes.

74 rs6044695 and rs2284912 were associated with fasting plasma glucose, and variants of rs2269023 were a

75 ded lack of measurement of lipid components, fasting plasma glucose, and visceral fat, and there migh

76 nefits of the lower diagnostic threshold for fasting plasma glucose are not well defined.

77 resulted in a approximately 25% reduction in fasting plasma glucose, associated with a approximately

78 creened for DM using glycated hemoglobin and fasting plasma glucose at TB treatment and after 3 month

79 cipants were screened for DM using HbA1c and fasting plasma glucose at TB treatment and after 3 month

80 y endpoints were the change from baseline in fasting plasma glucose at week 2 and week 28, and 2 h po

81 iers have marginally lower concentrations of fasting plasma glucose (beta = -0.18 mmol l(-1), P = 1.1

82 tance to roadways was associated with higher fasting plasma glucose (beta = 2.17 mg/dL; 95% CI: -0.24

83 ndex, blood pressure, total cholesterol, and fasting plasma glucose, better health behaviors (diet, p

84 2 inhibitors group had significantly reduced fasting plasma glucose by 0.69 mmol/L [1.32; 0.07], glyc

85 cinnamon and turmeric as well as changes in fasting plasma glucose, cholesterol, and triacylglycerol

86 d significantly after RDN, whereas mean (SD) fasting plasma glucose concentration (5.9 +/- 0.7 mmol/L

87 tes (mean age 38 years, body weight 81.7 kg, fasting plasma glucose concentration 83 mg/dL, and fasti

88 0.03 mmol x m(-2) x min(-1), P = 0.0009) and fasting plasma glucose concentration by 30% (to 10.8 +/-

89 Undiagnosed diabetes was defined as a fasting plasma glucose concentration of >/=126 mg/dL and

90 rly women in Denmark, we found that impaired fasting plasma glucose concentration was associated with

91 iometabolic risk factors (blood pressure and fasting plasma glucose concentration), along with binary

92 to <40 mg/dL, which is well below the normal fasting plasma glucose concentration.

93 as accompanied by sustained normalization of fasting plasma glucose concentrations and HbA1c levels a

94 ion were negatively correlated to changes in fasting plasma glucose concentrations and in the homeost

95 that, under normal physiological conditions, fasting plasma glucose concentrations are kept within a

96 Treatment increased fasting plasma glucose concentrations in all subjects (P

97 Fasting plasma glucose concentrations in each group were

98 Fasting plasma glucose concentrations increased after tr

99 we obtained essentially identical effects on fasting plasma glucose concentrations.

100 Fasting plasma glucose did not differ between trials (P

101 t, excessive gestational weight gain, raised fasting plasma glucose during pregnancy, short breastfee

102 he HFD induced insulin resistance, increased fasting plasma glucose, enhanced ceramide accumulation a

103 5-month intervals for up to 5 years or until fasting plasma glucose exceeded 140 mg/dl in Hispanic wo

104 rs890609/rs2269023 were also associated with fasting plasma glucose, fasting insulin and HOMA-IR.

105 Changes in fasting plasma glucose, fasting insulin, blood pressure,

106 etic resonance imaging and spectroscopy; (2) fasting plasma glucose, fasting plasma insulin (FPI), an

107 normal heart rate recovery added to impaired fasting plasma glucose for the prediction of death.

108 strategy, nor did titrating treatment using fasting plasma glucose (for areas without HbA1c testing)

109 ected 2 to 3 months after transplantation by fasting plasma glucose (fPG) >/= 7.0 mmol/L (>/= 126 mg/

110 osis, serum hemoglobin A1C (A1C) >/=6.5%, or fasting plasma glucose (FPG) >/=126 mg/dL, prediabetes a

111 30 years who were free of diabetes and had a fasting plasma glucose (FPG) <126 mg/dl at baseline.

112 IA severity correlated with fasting plasma glucose (FPG) (r = 0.662, P < 0.001) and

113 nately, tests such as hemoglobin A1c (HbA1c)/fasting plasma glucose (FPG) alone fail to diagnose or m

114 otype of rs964184 exhibited higher levels of fasting plasma glucose (FPG) and blood hemoglobin A1c (H

115 mated trends and their uncertainties in mean fasting plasma glucose (FPG) and diabetes prevalence for

116 ts all patients.We studied concentrations of fasting plasma glucose (FPG) and fasting insulin (FI) as

117 KLF6-IVS1-27 in healthy subjects and assayed fasting plasma glucose (FPG) and insulin sensitivities.

118 sociated with HS progression were changes in fasting plasma glucose (FPG) between biopsies (per 10 mg

119 sporter inhibition with empagliflozin on the fasting plasma glucose (FPG) concentration and beta-cell

120 been introduced that lowered the diagnostic fasting plasma glucose (FPG) concentration from 7.8 to 7

121 ich treatment most frequently attains target fasting plasma glucose (FPG) concentration of less than

122 We investigated the association of fasting plasma glucose (FPG) concentrations during pregn

123 c) is recommended for diabetes diagnosis but fasting plasma glucose (FPG) has been useful for identif

124 The sensitivity of fasting plasma glucose (FPG) in screening for new-onset

125 the associations between preconception blood fasting plasma glucose (FPG) level and subsequent pregna

126 hemoglobin A1c level of 6.5% or greater or a fasting plasma glucose (FPG) level of 126 mg/dL or great

127 measures of subgingival microbiota predicted fasting plasma glucose (FPG) longitudinally.

128 avenous glucose (AIR(gluc)) and the level of fasting plasma glucose (FPG) maintained in pancreas tran

129 ne HbA1c of 6.5% (48 mmol/mol) or greater or fasting plasma glucose (FPG) of 7.0 mmol/L or greater.

130 A fasting plasma glucose (FPG) test was used as the study

131 Fasting plasma glucose (FPG) was measured from capillary

132 Gestational fasting plasma glucose (FPG) was positively associated w

133 of self-report, medication use, measures of fasting plasma glucose (FPG), 2 h plasma glucose, and Hb

134 1Q (rs1044498) was associated with increased fasting plasma glucose (FPG), A1C, fasting insulin, and

135 w or measurements of hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and 2-hour plasma glucose

136 ressure (SBP), serum total cholesterol (TC), fasting plasma glucose (FPG), and body mass index (BMI)

137 baseline cut-point values of FINDRISC score, fasting plasma glucose (FPG), and HbA1c.

138 DE, which revealed association with HbA(1c), fasting plasma glucose (FPG), and mean fasting plasma gl

139 body mass index (BMI), blood pressure (BP), fasting plasma glucose (FPG), and type 2 diabetes (T2D).

140 let function was assessed by measurements of fasting plasma glucose (FPG), intravenous glucose disapp

141 es in hemoglobin (Hb) A1c (primary outcome), fasting plasma glucose (FPG), serum N(euro)-(carboxymeth

142 culated for glycated hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), total cholesterol (TC), tr

143 tors age, systolic blood pressure (SBP), and fasting plasma glucose (FPG), triglyceride, and high-den

144 olic blood pressures, body mass index (BMI), fasting plasma glucose (FPG), triglycerides (TG) and cho

145 pressure (SBP), total cholesterol (TC), and fasting plasma glucose (FPG).

146 s to assess progression from NGT to abnormal fasting plasma glucose (FPG; > or =6.1 mmol/l), abnormal

147 es Association (ADA) definition of diabetes (fasting plasma glucose [FPG] > or = 126 mg/dl on two occ

148 es with mild lifelong fasting hyperglycemia (fasting plasma glucose [FPG] 5.5-9.2 mmol/l, interquarti

149 DM patients (n = 10, age = 56 +/- 2.2 years, fasting plasma glucose [FPG] = 8.4 +/- 1.3 mmol/L, HbA(1

150 We used fasting plasma glucose, glucose tolerance tests, and sel

151 Waist circumference, body mass index, fasting plasma glucose, glycohemoglobin, low-density lip

152 pe 2 diabetes or abnormal glucose tolerance (fasting plasma glucose > or = 6.1 mmol/l or 2-h postchal

153 Diabetes was defined as a fasting plasma glucose > or = 7.0 mmol/L or treatment wi

154 s defined as casual glucose > or =200 mg/dL, fasting plasma glucose > or =126 mg/dL, or treatment.

155 diabetes at baseline (defined by treatment, fasting plasma glucose > or =7 or 2-h postchallenge gluc

156 ears for new cases of diabetes (treatment or fasting plasma glucose > or =7.0 mmol/l).

157 es adults) and >/= 88 cm (female adults); 2) fasting plasma glucose >/= 100 mg/dl; 3) blood pressure

158 The main outcome measures were diabetes (fasting plasma glucose >/= 126 mg/dL or taking medicatio

159 Participants who had a fasting plasma glucose >/=126 mg/dL and/or a 2-hour plas

160 >/=5.7 and <6.5% and (2) diabetes mellitus: fasting plasma glucose >/=126 mg/dL, 2-hour postload glu

161 Diabetes was defined as fasting plasma glucose >= 7.0 mmol/l (126 mg/dl), random

162 Fasting plasma glucose had weaker associations with thes

163 -sectional associations of glycemic markers (fasting plasma glucose, HbA(1C), and homeostasis model a

164 pancreas were recruited for measurements of fasting plasma glucose, HbA1c, intravenous glucose toler

165 ular reactivity and systolic blood pressure, fasting plasma glucose, HDL cholesterol, fasting plasma

166 Because fasting plasma glucose, hemoglobin A1c, and the oral glu

167 roups revealed no significant differences in fasting plasma glucose, hemoglobin A1c, fasting insulin

168 metabolic factors (high SBP, high BMI, high fasting plasma glucose, high total cholesterol, and low

169 No significant differences were found for fasting plasma glucose, high-density lipoprotein cholest

170 he effect of both wines on glycemic control (fasting plasma glucose, homeostatic model assessment of

171 expression in WAT inversely correlated with fasting plasma glucose in both obese mice and humans.

172 improves insulin sensitivity and normalizes fasting plasma glucose in diabetic UCD-T2DM rats, indepe

173 ary risks, high systolic blood pressure, and fasting plasma glucose in ranked attributable proportion

174 ng laboratory glycated hemoglobin (HbA1c) or fasting plasma glucose in TB patients.

175 er 3 weeks on a high fat diet, the decreased fasting plasma glucose in transgenic mice compared with

176 Fasting plasma glucose increased from 94 +/- 2 to 142 +/

177 were used to test for prediabetes, including fasting plasma glucose, insulin resistance (measured by

178 Fasting plasma glucose is a multigenic trait related to

179 Fasting plasma glucose is strongly and independently ass

180 bnormal, the prognosis for patients with low fasting plasma glucose is unclear.

181 of age with newly diagnosed type 2 diabetes (fasting plasma glucose level > or = 7.8 mmol/L [140 mg/d

182 nce (World Health Organization criteria plus fasting plasma glucose level >or=5.3 mmol/L [>or=95 mg/d

183 ated to waist girth, triglyceride level, and fasting plasma glucose level (all p's < 0.001).

184 The OGCT and fasting plasma glucose level (at a threshold of 4.7 mmol

185 ed changes in body weight, insulin dose, and fasting plasma glucose level at 24 weeks and during the

186 The fasting plasma glucose level had decreased at both time

187 lationship was found between CMT, HbA1c, and fasting plasma glucose level in either group (p=0.05).

188 outcomes associated with an increase in the fasting plasma glucose level of 1 SD (6.9 mg per decilit

189 ght patients aged 40 to 80 years with a mean fasting plasma glucose level of 12.0 mmol/L (216 mg/dL),

190 isk for diabetes (body mass index >24 kg/m2, fasting plasma glucose level of 5.2725 to 6.9375 mmol/L

191 was defined as a self-reported diagnosis or fasting plasma glucose level of 7.0 mmol/L (126 mg/dL) o

192 n level had poorer test characteristics than fasting plasma glucose level or the OGCT.

193 Data remained blinded if the fasting plasma glucose level was 105 mg per deciliter (5

194 The performance in prediction of fasting plasma glucose level was measured using 100 boot

195 s 7.5+/-1.2% in each group, whereas the mean fasting plasma glucose level was significantly lower in

196 Longer duration of diabetes and higher fasting plasma glucose level were associated with lower

197 of three glycemic criteria for prediabetes (fasting plasma glucose level, 100 to 125 mg per decilite

198 by a maximal exercise test on a treadmill), fasting plasma glucose level, and other clinical and per

199 nt for age, baseline cardiovascular disease, fasting plasma glucose level, high cholesterol level, ov

200 After further adjustment for fasting plasma glucose level, smoking, body mass index,

201 ner and exhibited a 37% (P<0.05) decrease in fasting plasma glucose level.

202 Secondary end points included the change in fasting plasma glucose level.

203 globin A1c level, and 171.3 (72.5) mg/dL for fasting plasma glucose level.

204 ars of quadrennial follow-up, was defined by fasting plasma glucose levels > or = 7.8 mmol/l at any t

205 ccurrence of one of four parameters: (i) two fasting plasma glucose levels >/= 126 mg/dL (>/= 7.0 mmo

206 kg/m2, RR = 1.64 [95% CI: 1.07-2.98]), high fasting plasma glucose levels (>/=126 mg/dL versus < 110

207 Fasting plasma glucose levels (Hedges g = 0.20; 95% CI,

208 ium in this population--were associated with fasting plasma glucose levels (P = 0.000017) and those 6

209 ting set, which is far superior to measuring fasting plasma glucose levels alone.

210 Participants with low fasting plasma glucose levels also had increased risk of

211 These changes were consistent with reduced fasting plasma glucose levels and altered expression of

212 women to investigate the association between fasting plasma glucose levels and cardiovascular disease

213 Elevated fasting plasma glucose levels associate with increased r

214 ory of diabetes in the ILS group, and higher fasting plasma glucose levels at baseline in the placebo

215 Fasting plasma glucose levels before the transplant are

216 the 8 mg/d metformin-rosiglitazone group and fasting plasma glucose levels by 2.2 mmol/L (39.8 mg/dL)

217 ant displayed significant worsening of their fasting plasma glucose levels during the 10-week observa

218 When used to target normal fasting plasma glucose levels for more than 6 years, ins

219 Participants with low fasting plasma glucose levels had a high risk of cardiov

220 We performed a genome scan for quantitative fasting plasma glucose levels in 320 families (1,514 sub

221 tal studies, administration of 2-AAA lowered fasting plasma glucose levels in mice fed both standard

222 Fasting plasma glucose levels in nondiabetic individuals

223 eproducibly associated with triglyceride and fasting plasma glucose levels in the general population.

224 Melatonin treatment significantly reduced fasting plasma glucose levels in the rats with DM.

225 Proportion of patients with fasting plasma glucose levels less than 126 mg/dL and Hb

226 ion of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular

227 ence of afternoon-examined participants with fasting plasma glucose levels of 7.0 mmol/L (126 mg/dL)

228 ldly diabetic phenotype, evidenced by higher fasting plasma glucose levels than wild-type mice.

229 tes and impaired fasting glucose levels, low fasting plasma glucose levels were also associated with

230 Body weight and fasting plasma glucose levels were determined weekly.

231 Fasting plasma glucose levels were greater in the NM gro

232 Mean (SD) fasting plasma glucose levels were higher in the morning

233 Fasting plasma glucose levels were reduced upon blockade

234 ndicated that high body mass index, elevated fasting plasma glucose levels, and nonalcoholic fatty li

235 everity of diabetes was evaluated by testing fasting plasma glucose levels, hemoglobin A1c levels, an

236 Glycosylated hemoglobin levels, fasting plasma glucose levels, insulin sensitivity, and

237 etes cases were identified by fasting or non-fasting plasma glucose levels, oral glucose tolerance te

238 Case-control studies reporting on fasting plasma glucose levels, plasma glucose levels aft

239 Standardized mean differences in fasting plasma glucose levels, plasma glucose levels aft

240 ability of dapagliflozin to improve fed and fasting plasma glucose levels.

241 Fasting plasma glucose, lipids, and 24-hour blood pressu

242 Blood samples were taken to assess fasting plasma glucose, low-density lipoprotein, high-de

243 Treatment was uptitrated to achieve target fasting plasma glucose <126 mg/dl; CHF medications were

244 and visceral adiposity in individuals with a fasting plasma glucose <6.4 mmol/l.

245 ory of cardiovascular disease, patients with fasting plasma glucose <70 mg/dL (<3.89 mmol/L) had a 3.

246 Although medical textbooks usually classify fasting plasma glucose <70 or 80 mg/dL (<3.89 or 4.44 mm

247 ears), drug-naive, type 2 diabetic subjects (fasting plasma glucose <or=10 mmol/l), we examined a rep

248 e (odds ratio 5.44 [2.63 to 11.27]), but not fasting plasma glucose (mean difference 0.03 mmol/L [-0.

249 can Diabetes Association guidelines based on fasting plasma glucose measurement and medication histor

250 ral-glucose-tolerance testing and semiannual fasting plasma glucose measurement.

251 and undiagnosed diabetes was determined with fasting plasma glucose measurements.

252 (1c), fasting plasma glucose (FPG), and mean fasting plasma glucose (mFPG) measured over 20 years.

253 Fasting plasma insulin, fasting plasma glucose, minimal model-derived insulin se

254 Liraglutide reduced mean fasting plasma glucose more than did exenatide (-1.61 mm

255 c intake and lower to normal metabolic rate, fasting plasma glucose, non-esterified fatty acids, chol

256 ated haemoglobin (HbA(1c)) of 8.5% (SD 1.1), fasting plasma glucose of 9.1 mmol/L (2.6), and weight o

257 e, which was defined as a confirmed level of fasting plasma glucose of more than 180 mg per deciliter

258 nge in the measurements of diabetic control (fasting plasma glucose or fructosamine) or by any change

259 There were no significant changes in fasting plasma glucose or lipids in conjunction with the

260 evealed no association with type 2 diabetes, fasting plasma glucose, or insulin sensitivity.

261 ch was fat loss, accompanied by decreases in fasting plasma glucose (P < 0.05) and triglycerides (P <

262 an overnight fast, women with GDM had higher fasting plasma glucose (P = 0.0001) and immunoreactive i

263 Fasting plasma glucose (P = 0.007) and homeostasis model

264 ion in TG (p = 0.001), HbA1c (p = 0.019) and fasting plasma glucose (p = 0.019) and significant incre

265 (P = 0.02), waist circumference (P < 0.001), fasting plasma glucose (P = 0.03), and triglycerides (P

266 nd postpartum weight reduction on changes in fasting plasma glucose (P-interaction = 0.03).

267 rs10401670 was also associated with fasting plasma glucose (Pe = 0.02, BMI adjusted) and mea

268 h body mass index, high blood pressure, high fasting plasma glucose, physical inactivity, and alcohol

269 had significantly lower glycated hemoglobin, fasting plasma glucose, plaque index, gingival index, pr

270 Body weight, fasting plasma glucose, plasma insulin, and intraperiton

271 imum inhibitory response correlated with the fasting plasma glucose (r = 0.75, P < 0.001) and insulin

272 n A1c values ranging from 5.7% to 6.4% or 2) fasting plasma glucose ranging from 100 to 125 mg/dL.

273 er response to gliclazide than to metformin (fasting plasma glucose reduction 4.7 vs 0.9 mmol/L, p=0.

274 Fasting plasma glucose remained an independent predictor

275 of only one of these tests is positive, then fasting plasma glucose should be tested to evaluate the

276 Fasting plasma glucose significantly decreased in the di

277 [-0.19 to -0.07], P<0.001, respectively; for fasting plasma glucose, standardized B=-0.09 [-0.15 to -

278 d the associations of body mass index (BMI), fasting plasma glucose, systolic blood pressure, and ser

279 , all once-weekly GLP-1RAs reduced HbA1c and fasting plasma glucose; taspoglutide, 20 mg, once-weekly

280 , and mice lacking hepatic Ppp1r3b had lower fasting plasma glucose than controls.

281 lipoprotein cholesterol, triglycerides, and fasting plasma glucose) that met criteria from the Natio

282 and FFA 17:0 were inversely associated with fasting plasma glucose, the area under the curve for glu

283 For a fasting plasma glucose threshold of 4.7 mmol/L (85 mg/dL

284 We used population distribution of fasting plasma glucose to measure exposure to higher-tha

285 mass index [BMI] as behavioral CVH metrics; fasting plasma glucose, total cholesterol, and blood pre

286 , ambulatory blood pressure monitoring (BP), fasting plasma glucose, triglycerides (TG), cholesterol

287 ignificantly associated with blood pressure, fasting plasma glucose, triglycerides, and high-density

288 s, with measurements of BMI, blood pressure, fasting plasma glucose, triglycerides, HDL cholesterol c

289 The diagnostic fasting plasma glucose value for afternoon-examined part

290 ving hemoglobin A1c levels less than 6.5% or fasting plasma glucose values less than 126 mg/dL withou

291 Fasting plasma glucose was also inversely correlated wit

292 Neither 2hPG nor fasting plasma glucose was associated with death-censore

293 Each 10-mg/dL increase in fasting plasma glucose was associated with higher odds o

294 Fasting plasma glucose was associated with unadjusted bu

295 Fasting plasma glucose was measured every 3 months, and

296 n plasma lipid profiles, but a small rise in fasting plasma glucose was observed.

297 the genetic risk score on 5-year changes in fasting plasma glucose was stronger in individuals who i

298 In addition, higher glycohemoglobin A1c and fasting plasma glucose were associated with lower retina

299 se tissue, blood pressure, serum lipids, and fasting plasma glucose) were collected.

300 is study was to determine the association of fasting plasma glucose with abnormal heart rate recovery